Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.50 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25308181 | 0.82 | TRIM24 (0.44) | POLBALDH1A3KDM4EALDH1A1MAPT | |
| SCHEMBL1133951 | 0.82 | TRIM24 (0.48) | POLBALDH1A3KDM4EALDH1A1MAPK1 | |
| SCHEMBL18634837 | 0.81 | POLB (0.53) | POLBKDM4ECNR2ALDH1A1MAPK1 | |
| SCHEMBL1134095 | 0.81 | ALDH1A1 (0.50) | POLBALDH1A3KDM4EALDH1A1TSHR | |
| SCHEMBL27150041 | 0.79 | ALDH3A1 (0.49) | POLBALDH3A1ALDH1A3KDM4EALDH1A1 | |
| SCHEMBL16755649 | 0.78 | ALDH1A1 (0.53) | KDM4EALDH1A1MAPK1KMT2ATSHR | |
| SCHEMBL16654217 | 0.78 | TAAR1 (0.57) | KDM4EALDH1A1KMT2ATSHRHDAC6 | |
| SCHEMBL1124372 | 0.77 | ALDH1A1 (0.55) | POLBALDH3A1ALDH1A3KDM4ECNR2 | |
| SCHEMBL30287647 | 0.77 | ALDH1A1 (0.55) | POLBALDH3A1ALDH1A3KDM4ECNR2 | |
| SCHEMBL12523748 | 0.77 | AOC3 (0.54) | POLBALDH3A1ALDH1A3KDM4ECNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105452233-A | Piperidine and azepane derivatives as prokineticin receptor modulators | TAKEDA PHARMACEUTICALS CO | 2016-03-30 | — | — | CN | claimed |
| EP-4228639-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 Therapeutics, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023154344-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230110165-A1 | Substituted Imidazo[4,5-c]pyridine Compounds and Compositions Thereof | PROXIMAGEN LLC (US) | 2023-04-13 | — | — | US | disclosed |
| US-11512082-B2 | Substituted imidazo[4,5-c]pyridine compounds and compositions thereof | PROXIMAGEN, LLC (US) | 2022-11-29 | — | — | US | disclosed |
| WO-2022081925-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-10968223-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200347059-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN, LLC (US) | 2020-11-05 | — | — | US | disclosed |
| US-10766897-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200262835-A1 | COMPOUNDS | PROXIMAGEN, LLC (US) | 2020-08-20 | — | — | US | disclosed |
| US-8349839-B2 | Inhibitors of HIV replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-08 | — | — | US | disclosed |
| WO-2013003383-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-01-03 | — | — | WO | disclosed |
| EP-2285800-B1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-16 | — | — | EP | disclosed |
| CN-102066360-A | Quinoline-or isoquinoline-substituted P2X7 antagonists | JANSSEN PHARMACEUTICA NV | 2011-05-18 | — | — | CN | disclosed |
| US-20110092481-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
| EP-2285800-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2011-02-23 | — | — | EP | disclosed |
| WO-2010115264-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261714-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261714-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| WO-2009132000-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11512082-B2 | Substituted imidazo[4,5-c]pyridine compounds and compositions thereof | PNPO, XDH, EPX | POLB 1538/4885ALDH3A1 596/4885ALDH1A3 2027/4885 |
| US-20110092481-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | P2RX7, P2RX1, P2RX3 | POLB 3362/4885ALDH3A1 2446/4885ALDH1A3 3518/4885 |
| US-10766897-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PNPO, SSB, XDH | POLB 759/4885ALDH3A1 808/4885ALDH1A3 2621/4885 |
| US-10968223-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PNPO, PPOX, SCO2 | POLB 1538/4885ALDH3A1 349/4885ALDH1A3 1380/4885 |
| US-20230110165-A1 | Substituted Imidazo[4,5-c]pyridine Compounds and Compositions Thereof | PNPO, XDH, EPX | POLB 1538/4885ALDH3A1 596/4885ALDH1A3 2027/4885 |
| US-20100261714-A1 | INHIBITORS OF HIV REPLICATION | RTF2, POLR1A, REV1 | POLB 48/4885ALDH3A1 1650/4885ALDH1A3 2981/4885 |
| US-20200347059-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PNPO, PPOX, SCO2 | POLB 1538/4885ALDH3A1 349/4885ALDH1A3 1380/4885 |
| US-20200262835-A1 | COMPOUNDS | QSOX1, AOX1, EPX | POLB 1310/4885ALDH3A1 1030/4885ALDH1A3 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.